1.Neurological Abnormality Could be the First and Only Symptom of Familial Hemophagocytic Lymphohistiocytosis: Report of Two Families.
Yun-Ze ZHAO ; Hua CHENG ; Chang-Hong DING ; Hong-Hao MA ; Tong-Li HAN ; Jiu-Wei LI ; Dong WANG ; Zhi-Gang LI ; Tian-You WANG ; Rui ZHANG
Chinese Medical Journal 2018;131(24):3004-3006
2.Familial Hemophagocytic Lymphohistiocytosis Type 2 in a Korean Infant With Compound Heterozygous PRF1 Defects Involving a PRF1 Mutation, c.1091T>G.
Min Sun KIM ; Young Uk CHO ; Seongsoo JANG ; Eul Ju SEO ; Ho Joon IM ; Chan Jeoung PARK
Annals of Laboratory Medicine 2017;37(2):162-165
No abstract available.
Asian Continental Ancestry Group/*genetics
;
Base Sequence
;
Bone Marrow Cells/cytology/pathology
;
Cytomegalovirus Infections/diagnosis
;
Epstein-Barr Virus Infections/diagnosis
;
Female
;
Flow Cytometry
;
Heterozygote
;
Humans
;
Infant
;
Killer Cells, Natural/cytology/immunology
;
Lymphohistiocytosis, Hemophagocytic/*diagnosis/genetics
;
Perforin/*genetics
;
Phagocytosis
;
Polymorphism, Single Nucleotide
;
Republic of Korea
;
Sequence Analysis, DNA
4.Hemophagocytic Lymphohistiocytosis
Clinical Pediatric Hematology-Oncology 2017;24(1):11-20
Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal disease caused by dysregulated immune responses and overwhelming inflammation to infectious or other triggers of the immune system. HLH may be inherited (primary) or may be secondary to any severe infection, malignancy or rheumatologic disease. Clinical progress of HLH is usually rapid and fatal. Early recognition and assessment of potential causes of HLH is critical to improve survival. Urgent treatment is needed for immunosuppression and degradation of the activated antigen. Over the last two decades, research on genetics and pathophysiology of HLH has much improved treatment outcome of the patient. Here, we review recent advances in our understanding of etiology, pathophysiology, diagnosis and treatment of HLH.
Diagnosis
;
Genetics
;
Humans
;
Immune System
;
Immunosuppression
;
Inflammation
;
Lymphohistiocytosis, Hemophagocytic
;
Treatment Outcome
5.First Report on Familial Hemophagocytic Lymphohistiocytosis with an Abnormal Immunophenotype and T Cell Monoclonality in Korea.
Sang Yong SHIN ; Kyunghoon LEE ; Mi Ae JANG ; Seung Tae LEE ; Keon Hee YOO ; Hong Hoe KOO ; Dae Shick KIM ; Hee Jin KIM ; Sun Hee KIM
Annals of Laboratory Medicine 2015;35(1):155-158
No abstract available.
Bone Marrow/metabolism/pathology
;
DNA Mutational Analysis
;
Gene Rearrangement, T-Lymphocyte
;
Humans
;
Immunophenotyping
;
Infant
;
Lymphohistiocytosis, Hemophagocytic/*diagnosis
;
Male
;
Membrane Proteins/chemistry/genetics
;
Polymorphism, Single-Stranded Conformational
;
Republic of Korea
;
T-Lymphocytes/immunology/*metabolism
6.Advances in studies on hemophagocytic lymphohistiocytosis.
Chinese Journal of Pediatrics 2014;52(4):267-270
7.Analysis of clinical phenotype and genetic mutations of a pedigree of familial hemophagocytic lymphohistiocytosis.
Shuwen SUN ; Xia GUO ; Yiping ZHU ; Xue YANG ; Qiang LI ; Ju GAO
Chinese Journal of Medical Genetics 2014;31(5):570-573
OBJECTIVETo analyze mutations in a pedigree of familial hemophagocytic lymphohistiocytosis (FHLH) from Sichuan and provide genetic counseling for the family.
METHODSClinical data of a case with FHLH diagnosed at West China Second Hospital was retrospectively analyzed. Genomic DNA was extracted from peripheral blood samples of the proband and his family members. Eight candidate genes for primary HLH were amplified with PCR and analyzed by direct sequencing.
RESULTSThe proband was diagnosed as HLH based on clinical manifestations of recurrent fever for 2 months, hepatosplenomegaly, lymphadenopathy, pancytopenia, hyperferritinemia, and decreased fibrinogen and hemophagocytosis in bone marrow. Genetic testing for primary HLH was carried out considering the relapse of illness after hormone therapy for 8 weeks and the family history. The results of gene sequencing showed that the proband has carried compound heterozygous mutations in PRF1 gene (c.1349C> T in exon 3 and c.445G> A in exon 2). His father has carried a heterozygous mutation (c.445G> A in exon 2) and nonsense mutation (c.900C> T in exon 3), and his mother carried a heterozygous mutation (c.1349C> T in exon 3). Both c.1349C> T and c.445G> A have been previously reported as pathogenic mutations.
CONCLUSIONThe family has been diagnosed as familial HLH type 2 based on clinical and laboratory examinations and molecular genetic testing. Gene sequencing has indicated that is was a recessive type familial HLH.
Base Sequence ; DNA Mutational Analysis ; Exons ; genetics ; Family Health ; Female ; Genes, Recessive ; genetics ; Genetic Predisposition to Disease ; genetics ; Heterozygote ; Humans ; Lymphohistiocytosis, Hemophagocytic ; diagnosis ; genetics ; Male ; Mutation ; Pedigree ; Perforin ; genetics ; Phenotype ; Polymerase Chain Reaction ; Retrospective Studies
8.Research advances in molecular genetics and treatment of familial hemophagocytic lymphohistiocytosis.
Chinese Journal of Contemporary Pediatrics 2013;15(11):965-969
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening syndrome characterized by pancytopenia and multiple organ infiltrations of lymphocytes and histiocytes with proliferation and hemohpagocytic activity. HLH is classified as primary (or familial) and secondary. Familial HLH is common in infants and young children, and is related to genetic defects. This article aims to review research advances on PRF1, UNC13D, STX11 and STXBP2, as well as the other 5 genes associated with familial HLH based on molecular genetics, and to summarize diagnosis and treatment methods for this disease.
Humans
;
Lymphohistiocytosis, Hemophagocytic
;
diagnosis
;
etiology
;
genetics
;
therapy
;
Molecular Biology
9.Progress of diagnosis and treatment of X-linked inhibitor of apoptosis deficiency.
Xi YANG ; Hirokazu KANEGANE ; Toshio MIYAWAKI
Chinese Journal of Pediatrics 2012;50(6):428-430
Amino Acid Sequence
;
Base Sequence
;
Child
;
Flow Cytometry
;
methods
;
Genes, X-Linked
;
Hematopoietic Stem Cell Transplantation
;
Humans
;
Lymphocytes
;
metabolism
;
Lymphohistiocytosis, Hemophagocytic
;
diagnosis
;
genetics
;
therapy
;
Lymphoproliferative Disorders
;
diagnosis
;
genetics
;
therapy
;
Mutation
;
Transplantation, Homologous
;
X-Linked Inhibitor of Apoptosis Protein
;
deficiency
;
genetics
;
metabolism
10.Screening for cytotoxic defects with flow cytometric detection of CD107α on natural killer cells and cytotoxic lymphocyte cells.
Jing WANG ; Zheng LIU ; Li-ping JIANG ; Yun-fei AN ; Xiao-dong ZHAO
Chinese Journal of Pediatrics 2012;50(5):386-391
OBJECTIVETo establish a novel flow cytometry-based assay for measuring the expression of lysosomal-associated membrane protein 1 (LAMP-1, CD107α) on the cell surface of natural killer (NK) cells and cytotoxic T lymphocyte (CTL) and evaluate the screening value of this assay for cytotoxic defects-related diseases such as familial hemophagocytic lymphopro-liferative (FHL) syndrome.
METHODThree suspected Chediak-Higashi Syndrome (CHS) patients, three suspected FHL patients and 10 healthy children were enrolled in the study from October 2010 to June 2011. Their PBMCs were separated and activated overnight with IL-2. After the granule release of NK cells activated by phytohemagglutinin (PHA) and CD8+T cells by anti-CD3, the CD107α expression were analyzed by flow cytometry. The peripheral blood DNA and RNA of the patients were extracted to analyze the pathogenic genes via DNA-PCR/RT-PCR and direct sequencing.
RESULTThe CD107α expression on CTL in the ten healthy children significantly increased after activation by anti-CD3 [(0.18 ± 0.07)% vs. (4.47 ± 2.36)%, P < 0.05] and NK cells after activation by PHA [(0.27 ± 0.07)% vs. (5.80 ± 2.83)%, P < 0.05]. The frequency of CD107α-expression NK cells in three suspected CHS after activation was significantly elevated when compared with the healthy control [0.5%, 0.6% vs. (5.80 ± 2.83)%] except patient 2. After the anti-CD3 activation, the frequency of CD107α expression on CTL cells also showed no significant difference [0.3%, 0.9%, 0.2% vs. (4.47 ± 2.36)%] in three patients. All of their mean fluorescence intensity (MFI) showed the same trend. Patient 1 and 3 were identified to have LYST mutations (Patient 1: c.5411-5414 del TTTC, L1741fsX1758 and c.7975 C > T, R2596X; Patient 3: c.4863G > A, R1563H and c.5392-5393delAA, E1739fsX1756). There was no mutation identified in the LYST gene for patient 2. CD107α expression of NK cells and CTL in the suspected FHL patients and in mirror of these findings, no underlying gene variation of PRF, MUNC13-4 and STX11 were identified.
CONCLUSIONWe developed a method to quantitatively assess cytotoxicity of the NK cells and CTL by measuring the expression of CD107α on the cell membrane, which appeared to be an effective and rapid screening test for cytotoxic defects-related diseases such as FHL and other HLH secondary to primary immunodeficiency.
Case-Control Studies ; Cell Degranulation ; immunology ; Cell Membrane ; metabolism ; Chediak-Higashi Syndrome ; diagnosis ; genetics ; immunology ; metabolism ; Child, Preschool ; Cytotoxicity, Immunologic ; Female ; Flow Cytometry ; methods ; Humans ; Infant ; Interleukin-2 ; metabolism ; Killer Cells, Natural ; immunology ; metabolism ; Lymphohistiocytosis, Hemophagocytic ; diagnosis ; genetics ; immunology ; metabolism ; Lysosomal-Associated Membrane Protein 1 ; metabolism ; Male ; Mutation ; Phytohemagglutinins ; metabolism ; T-Lymphocytes, Cytotoxic ; immunology ; metabolism

Result Analysis
Print
Save
E-mail